New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
10:55 EDTBNNY, USG, DYN, BDSI, IDIX, SLXP, CCIH, ACHN, VIP, NKTRHigh option volume stocks:
High option volume stocks: BNNY VIP ACHN CCIH SLXP IDIX BDSI DYN USG NKTR
News For BNNY;VIP;ACHN;CCIH;SLXP;IDIX;BDSI;DYN;USG;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 13, 2014
10:08 EDTUSGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:52 EDTUSGUS Building Products & Homebuilding sector lowered at Barclays
Subscribe for More Information
06:07 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Subscribe for More Information
05:54 EDTUSGUSG upgraded to Overweight from Equal Weight at Barclays
Subscribe for More Information
October 10, 2014
10:01 EDTBDSIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:02 EDTBDSIBioDelivery Sciences downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
05:59 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Stocks with implied volatility above IV index mean; Avon Products (AVP) 61, Achillion (ACHN) 200 according to iVolatility.
October 9, 2014
11:14 EDTSLXPAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
08:50 EDTSLXPAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
06:08 EDTACHNStocks with implied volatility above IV index mean; AVP ACHN
Stocks with implied volatility above IV index mean; Avon Products (AVP) 60, Achillion (ACHN) 195 according to iVolatility.
October 8, 2014
16:26 EDTACHNOn The Fly: Closing Wrap
Subscribe for More Information
15:49 EDTACHNAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
08:42 EDTSLXPSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
08:31 EDTSLXPSalix announces FDA granted final approval for UCERIS
Subscribe for More Information
06:23 EDTSLXPActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
06:11 EDTDYNDynegy 22.5M share Secondary priced at $31.00
Subscribe for More Information
October 7, 2014
15:21 EDTSLXPAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
10:56 EDTACHNOptions with increasing implied volatility
Subscribe for More Information
09:36 EDTACHNActive equity options trading on open
Subscribe for More Information
07:48 EDTSLXPSalix reinstated with a Buy at Jefferies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use